Literature DB >> 14644890

Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.

Michael K Gould1, Ware G Kuschner, Chara E Rydzak, Courtney C Maclean, Anita N Demas, Hidenobu Shigemitsu, Jo Kay Chan, Douglas K Owens.   

Abstract

PURPOSE: To compare the diagnostic accuracy of computed tomography (CT) and positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) for mediastinal staging in patients with non-small-cell lung cancer and to determine whether test results are conditionally dependent (the sensitivity and specificity of FDG-PET depend on the presence or absence of enlarged mediastinal lymph nodes on CT). DATA SOURCES: Computerized search of MEDLINE, EMBASE, BIOSIS, and CancerLit through March 2003 and reference lists of retrieved studies and review articles. STUDY SELECTION: Studies in any language that examined FDG-PET for mediastinal staging in patients with known or suspected non-small-cell lung cancer, enrolled at least 10 participants (including at least 5 participants with mediastinal metastasis), and provided enough data to permit calculation of sensitivity and specificity for identifying lymph node involvement. DATA EXTRACTION: One reviewer (of non-English-language studies) or 2 reviewers (of English-language studies) independently evaluated studies for inclusion, rated methodologic quality, and abstracted relevant data. DATA SYNTHESIS: Thirty-nine studies met inclusion criteria. Methodologic quality varied, but few aspects of study quality affected diagnostic accuracy. The authors constructed summary receiver-operating characteristic curves for CT and FDG-PET. Positron emission tomography with 18-fluorodeoxyglucose was more accurate than CT for identifying lymph node involvement (P < 0.001). For CT, median sensitivity and specificity were 61% (interquartile range, 50% to 71%) and 79% (interquartile range, 66% to 89%), respectively. For FDG-PET, median sensitivity and specificity were 85% (interquartile range, 67% to 91%) and 90% (interquartile range, 82% to 96%), respectively. Fourteen studies provided information about the conditional test performance of CT and FDG-PET. Positron emission tomography with 18-fluorodeoxyglucose was more sensitive but less specific when CT showed enlarged lymph nodes (median sensitivity, 100% [interquartile range, 90% to 100%]; median specificity, 78% [interquartile range, 68% to 100%]) than when CT showed no lymph node enlargement (median sensitivity, 82% [interquartile range, 65% to 100%]; median specificity, 93% [interquartile range, 92% to 100%]; P = 0.002).
CONCLUSIONS: Positron emission tomography with 18-fluorodeoxyglucose is more accurate than CT for mediastinal staging. Positron emission tomography with 18-fluorodeoxyglucose is more sensitive but less specific when CT shows enlarged mediastinal lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644890     DOI: 10.7326/0003-4819-139-11-200311180-00013

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  121 in total

1.  The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours.

Authors:  Bernadette G Dijkman; Olga C J Schuurbiers; Dennis Vriens; Monika Looijen-Salamon; Johan Bussink; Johanna N H Timmer-Bonte; Miranda M Snoeren; Wim J G Oyen; Henricus F M van der Heijden; Lioe-Fee de Geus-Oei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-10       Impact factor: 9.236

Review 2.  Ultrasound techniques in the evaluation of the mediastinum, part I: endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) and transcutaneous mediastinal ultrasound (TMUS), introduction into ultrasound techniques.

Authors:  Christoph Frank Dietrich; Jouke Tabe Annema; Paul Clementsen; Xin Wu Cui; Mathias Maximilian Borst; Christian Jenssen
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

3.  Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer.

Authors:  Paul Flechsig; Peter Choyke; Clemens Kratochwil; Arne Warth; Gerald Antoch; Tim Holland Letz; Daniel Rath; Viktoria Eichwald; Peter E Huber; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

4.  Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer.

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01       Impact factor: 9.236

5.  Evolution and science, progress and change.

Authors:  Frank C Detterbeck
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

6.  Experiences and benefits of positron emitted tomography-computed tomography (PET-CT) combined with video-assisted thoracoscopic surgery (VATS) in the diagnosis of Stage 1 sarcoidosis.

Authors:  Shi-Ping Luh; Tzu-Chin Wu; Yao-Tung Wang; Thomas Chang-Yao Tsao; Jia-Yuh Chen
Journal:  J Zhejiang Univ Sci B       Date:  2007-06       Impact factor: 3.066

Review 7.  Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis.

Authors:  Erik Folch; Daniel B Costa; Jeffrey Wright; Paul A VanderLaan
Journal:  Transl Lung Cancer Res       Date:  2015-08

8.  Ultrasound guided cytological aspiration of supraclavicular lymph nodes in patients with suspected lung cancer.

Authors:  M Kumaran; R E Benamore; R Vaidhyanath; S Muller; C J Richards; M D Peake; J J Entwisle
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

9.  Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer.

Authors:  Koko Ishida; Takashi Hirose; Junichi Yokouchi; Yasunari Oki; Sojiro Kusumoto; Tomohide Sugiyama; Hiroo Ishida; Takao Shirai; Masanao Nakashima; Toshimitsu Yamaoka; Tsukasa Ohnishi; Tohru Ohmori; Yoshikazu Kagami
Journal:  Mol Clin Oncol       Date:  2014-02-07

10.  The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.

Authors:  Pierre Starkov; Todd A Aguilera; Daniel I Golden; David B Shultz; Nicholas Trakul; Peter G Maxim; Quynh-Thu Le; Billy W Loo; Maximillan Diehn; Adrien Depeursinge; Daniel L Rubin
Journal:  Br J Radiol       Date:  2018-11-20       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.